Search results for 100% Pass Quiz 2024 High Pass-Rate Pegasystems PEGACPSSA23V1: Certified Pega Senior System Architect 23 Unlimited Exam Practice 🐉 Search for 《 PEGACPSSA23V1 》 and obtain a free download on ➠ www.pdfvce.com 🠰 ↙Real PEGACPSSA23V1 Exam Answers - 3356 results

article

Advanced techniques and applications of LC-MS in small molecule drug discovery

16 June 2016 | By Baiwei Lin (Genentech Inc.), Chunang Gu (Genentech Inc.), Joseph Pease (Genentech Inc.), Kate Comstock (formerly of Roche)

A key process in drug discovery is the ability to identify new drug candidates by screening chemical libraries of small molecules, natural products or extracts against a biological target and selecting lead compounds with desirable therapeutic effects. Medicinal chemistry has the challenging role of not only ensuring that the chemical…

article

A picture is worth a thousand endpoints: high-content imaging in drug discovery

12 September 2016 | By Debra Taylor (MRC Technology), Emilie Bureau (MRC Technology), Janet Brownlees (MRC Technology)

Over the past few years several factors in the drug discovery industry have come together to drive an increased interest and subsequent surge in the use of high-content imaging. These include the high costs of attrition in the clinic due to lack of efficacy; increased hurdles and rising costs to…

article

Kickstarting the use of AI for biotechs: part two

24 May 2024 | By Dr Raminderpal Singh (HitchhikersAI)

Traditional wet lab scientists working on target discovery, drug identification and drug optimisation have an opportunity to catch up with their AI-enabled peers – but why should they, and how? In this article – the second of a three-part series – Dr Raminderpal Singh touches on methods that are being…

article

Human iPSC-derived functional cells are revolutionising phenotypic drug discovery and development

4 September 2018 | By Arie Reijerkerk, Farbod Famili, Mieke Doornbos, Stefan Braam

Effective drug discovery and development relies largely on the availability of predictive pre-clinical model systems; the absence of which has contributed to late-stage drug failures and high expenditures. New industry acceptance of human induced pluripotent stem cell (hiPSC)-derived cardiomyocyte assay systems for regulatory safety pharmacology is now resulting in broad…

news

Immunocore ranks high in the Sunday Times Hiscox Tech Track 100

7 September 2015 | By Victoria White

Immunocore has been ranked as the Number one company in the southeast region of the UK and number nine overall in the Sunday Times Hiscox Tech Track 100...

article

The relevance of homogeneous radiometric assays in modern drug discovery

14 February 2016 | By Gabriele Sorg (Hit Discovery Constance), Horst Flotow (Singapore Screening Centre)

In the past two decades, several alternative, non-radiometric assay formats have been developed for the high-throughput screening (HTS) of target classes such as protein kinases, which were previously screened using radiometric assays. Radiometric screening (and the expertise to perform such HTS) has thus declined in recent years...

article

Phenotypic profiling in drug discovery

5 June 2019 | By Ina Rothenaigner, Kamyar Hadian, Sean Lin

Image-based phenotypic profiling of small molecules has been used for identification and characterisation of small molecules in drug discovery and can provide important insights into their mechanisms of action (MOA). This article discusses the use of phenotypic profiling in drug discovery and how machine-learning algorithms could help improve objectivity, processing…

article

Trends in contemporary microscopy

24 September 2015 | By Dimitri Scholz (University College Dublin), Jeremy Simpson (University College Dublin)

In the biomedical arena the imaging of biological samples has long been a mainstay technology, not only furthering our understanding of fundamental biology, but also playing a key role in designing strategies and therapies to combat infection and disease...

article

Part one: what can scientists do with LLMs today?

24 June 2024 | By Dr Raminderpal Singh (HitchhikersAI)

Recently there have been a flurry of announcements from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the first of a three-part series, Dr Raminderpal Singh explores what LLMs are, how early stage biotechs can take advantage of them, and what challenges they…

article

Kickstarting the use of AI for biotechs: part one

15 May 2024 | By Dr Raminderpal Singh (HitchhikersAI)

Traditional wet lab scientists working on target discovery, drug identification and drug optimisation have an opportunity to catch-up with their AI-enabled peers – but why should they, and how? In this article – the first of a three-part series – Dr Raminderpal Singh seeks to demystify the topic by outlining…

article

High-content imaging: challenges of the 3D world

17 June 2019 | By Jeremy C. Simpson, Margaritha M. Mysior

The potential of three-dimensional cell culture models is now well-recognised by scientists; however, there are still some challenges. Margaritha Mysior and Jeremy Simpson address some of the common challenges of working with spheroids and organoid models – including how they are developed and how to obtain high-resolution, high-content images and…

article

Academic high-throughput screening; Opportunities for change

9 April 2015 | By Tim Hammonds (Deputy Director of Discovery: CRT Discovery Laboratories)

Tim Hammonds from Cancer Research Technology Discoveries explains how academic HTS laboratories came into being and outlines the challenges facing the new HTS model...

article

Expanding accessible chemical space through automated high-throughput experimentation

6 April 2021 | By Dr Sam Liver (The Rosalind Franklin Institute)

Dr Sam Liver, Manager of the High-Throughput Molecular Discovery Laboratory at the Rosalind Franklin Institute, explains how lab automation in the form of machine learning and high‑throughput experimentation (HTE) can be implemented to enhance productivity in autonomous molecular discovery.

news

Novel targeted treatment shows efficacy in treating high-risk solid tumours

25 August 2020 | By Hannah Balfour (Drug Target Review)

The prodrug developed by researchers caused long-term remission in all murine models of high-risk or drug-resistant cancers with fewer side-effects than a comparable drug.

article

Developability assessment of therapeutic antibodies

8 March 2017 | By David Matthews (MRC Technology), Lone Friis (MRC Technology)

Developability assessment is a broad term covering the evaluation of potential therapeutic candidates’ drug-like properties, manufacturability and safety profile. It is important to carry out this assessment as early as possible in the pre-clinical stage development to select the candidate with the most stable profile. This can minimise the risks…